Patent · US Active

Oral suspension of prednisolone acetate

US8461139B2 · kind B2 · utility

0Cited by
20References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 30, 2012
Grant dateJun 11, 2013
Priority date
Expiry dateMay 30, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.